openPR Logo
Press release

Investigation announced for Long-Term Investors in Axsome Therapeutics, Inc. (NASDAQ: AXSM) concerning potential Wrongdoing

09-23-2021 12:37 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in Axsome Therapeutics, Inc. (NASDAQ: AXSM) shares over potential wrongdoing.

An investigation on behalf of investors in Axsome Therapeutics, Inc. (NASDAQ: AXSM) shares over potential wrongdoing.

Certain directors of Axsome Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.

Investors who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Axsome Therapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders.

New York based Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.

Axsome Therapeutics, Inc. (NASDAQ: AXSM) disclosed on August 9, 2021, that the FDA had found deficiencies with its New Drug Application (NDA) for AXS-05. The Company claimed it was attempting to determine the nature of the deficiencies, but that this announcement may delay the approval of AXS-05.

Shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) declined $74.10 per share on June 28, 2021, to as low as $19.38 per share on August 19, 2021.

Those who purchased shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in Axsome Therapeutics, Inc. (NASDAQ: AXSM) concerning potential Wrongdoing here

News-ID: 2403319 • Views: 862

More Releases from Shareholders Foundation

Investigation announced for Investors of Spirit of Texas Bancshares, Inc. (NASDA …
An investigation on behalf of investors, who currently hold shares of Spirit of Texas Bancshares, Inc. (NASDAQ: STXB), was announced concerning whether the takeover of Spirit of Texas Bancshares, Inc. is unfair to NASDAQ: STXB stockholders. Investors who purchased shares of Spirit of Texas Bancshares, Inc. (NASDAQ: STXB) and currently hold any of those NASDAQ: STXB shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
Investigation announced for Investors in shares of Rollins, Inc. (NYSE: ROL) ove …
An investigation was announced concerning potential securities laws violations by Rollins, Inc. in connection with certain financial statements. Investors who purchased shares of Rollins, Inc. (NYSE: ROL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Rollins, Inc. (NYSE: ROL) concerning whether a series of statements
Investigation announced for Investors in NASDAQ: FFIE over possible Wrongdoing a …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Faraday Future Intelligent Electric Inc. Investors who purchased shares of Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Faraday Future Intelligent Electric Inc. directors breached their fiduciary duties and caused damage
Investigation announced for NASDAQ: MRTX Investors over possible Wrongdoing at M …
Certain directors of Mirati Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. Investors who purchased shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Mirati Therapeutics, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders. San Diego, CA based Mirati

All 5 Releases


More Releases for Axsome

Depression - Pipeline Review & Swot Analysis by key Manufacturers Atai Life Scie …
A new independent 668 page research with title 'Depression - Pipeline Review, H1 2020' guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions like North America, South America, Asia & Pacific, Europe & MEA (Middle East and Africa) and important players/vendors such as Acadia Pharmaceuticals Inc, Adamed Sp zoo, Addex Therapeutics Ltd, Aequus Pharmaceuticals Inc, Aision Biotechnologies Inc, Alkermes Plc etc.
Meloxicam Market Global Sales, Revenue, Price and Gross Margin Forecast To 2028 …
This detailed market study covers meloxicam market growth potentials which can assist the stake holders to understand key trends and prospects in meloxicam market identifying the growth opportunities and competitive scenarios. The report also focuses on data from different primary and secondary sources, and is analyzed using various tools. It helps to gain insights into the market's growth potential, which can help investors identify scope and opportunities. The analysis also
Global Nicotine Addiction Treatment Market Statistics, Facts and Figures, Growth …
Global nicotine addiction treatment market is rising gradually with a healthy CAGR in the forecast period of 2019-2026. Government policies and initiatives to offer a fund to many research institute and pharmaceuticals companies for developing novel therapy and increase dependency of tobacco products are the key factors for market growth. Nicotine Addiction Treatment is a professional and a detailed report focusing on primary and secondary drivers, market share, market size, sales
Meloxicam Market Analysis 2020-2026 with Industry Leaders Profiles, Growth Prosp …
Complete study of the global Meloxicam market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Meloxicam industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the researchers. They have also provided accurate
Global Nicotine Addiction Treatment Market Latest Innovative Solutions to Boost …
Global nicotine addiction treatment market is rising gradually with a healthy CAGR in the forecast period of 2019-2026. Government policies and initiatives to offer a fund to many research institute and pharmaceuticals companies for developing novel therapy and increase dependency of tobacco products are the key factors for market growth Nicotine addiction treatment report provides complete background analysis of the healthcare industry which includes an assessment of the parental market. All
Complex Regional Pain Syndrome (CRPS) Therapeutics Clinical Trials & Results | A …
Complex regional pain syndrome (CRPS) is a type of chronic pain that affects one limb of the body (hand, leg, arm, or foot). The condition generally arises due to severe injuries or malfunctioning of central and peripheral nervous systems. Download the sample report @ https://www.pharmaproff.com/request-sample/1096 CRPS is categorized into two main types: CRPS-I and CRPS-II. CRPS-I is associated with unconfirmed nerve injury; whereas, CRPS-II is associated with confirmed nerve injury. CRPS